FI915719A0 - Gallsyraderivat, foerfarande foer deras framstaellning och anvaendning av denna foerening som laekemedel. - Google Patents

Gallsyraderivat, foerfarande foer deras framstaellning och anvaendning av denna foerening som laekemedel.

Info

Publication number
FI915719A0
FI915719A0 FI915719A FI915719A FI915719A0 FI 915719 A0 FI915719 A0 FI 915719A0 FI 915719 A FI915719 A FI 915719A FI 915719 A FI915719 A FI 915719A FI 915719 A0 FI915719 A0 FI 915719A0
Authority
FI
Finland
Prior art keywords
bile acid
gallsyraderivat
foerening
denna
foerfarande foer
Prior art date
Application number
FI915719A
Other languages
English (en)
Other versions
FI106800B (fi
FI915719A (fi
Inventor
Werner Kramer
Guenther Wess
Stefan Muellner
Horst Neubaer
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of FI915719A0 publication Critical patent/FI915719A0/fi
Publication of FI915719A publication Critical patent/FI915719A/fi
Application granted granted Critical
Publication of FI106800B publication Critical patent/FI106800B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C07J41/0016—Oximes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C07J41/0061—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Obesity (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Motorcycle And Bicycle Frame (AREA)
  • Train Traffic Observation, Control, And Security (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FI915719A 1990-12-06 1991-12-04 Menetelmä uusien terapeuttisesti käyttökelpoisten dimeeristen sappihappojohdannaisten valmistamiseksi FI106800B (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4038833 1990-12-06
DE4038833 1990-12-06

Publications (3)

Publication Number Publication Date
FI915719A0 true FI915719A0 (fi) 1991-12-04
FI915719A FI915719A (fi) 1992-06-07
FI106800B FI106800B (fi) 2001-04-12

Family

ID=6419672

Family Applications (1)

Application Number Title Priority Date Filing Date
FI915719A FI106800B (fi) 1990-12-06 1991-12-04 Menetelmä uusien terapeuttisesti käyttökelpoisten dimeeristen sappihappojohdannaisten valmistamiseksi

Country Status (23)

Country Link
US (1) US5250524A (fi)
EP (1) EP0489423B1 (fi)
JP (1) JP3237882B2 (fi)
KR (1) KR100221690B1 (fi)
AT (1) ATE144988T1 (fi)
AU (1) AU649089B2 (fi)
CA (1) CA2057099C (fi)
CZ (1) CZ281075B6 (fi)
DE (1) DE59108326D1 (fi)
DK (1) DK0489423T3 (fi)
ES (1) ES2096614T3 (fi)
FI (1) FI106800B (fi)
GR (1) GR3021572T3 (fi)
HR (1) HRP940751B1 (fi)
HU (2) HU213402B (fi)
IE (1) IE914235A1 (fi)
IL (1) IL100240A (fi)
NO (1) NO304187B1 (fi)
NZ (1) NZ240846A (fi)
PT (1) PT99713B (fi)
SI (1) SI9111899B (fi)
YU (1) YU48636B (fi)
ZA (1) ZA919605B (fi)

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795870A (en) * 1991-12-13 1998-08-18 Trustees Of Princeton University Compositions and methods for cell transformation
EP0549967B1 (de) * 1991-12-20 1996-03-13 Hoechst Aktiengesellschaft Polymere und Oligomere von Gallensäurederivaten, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
NZ245504A (en) * 1991-12-20 1995-08-28 Hoechst Ag Bile acid derivatives containing an ethylenically unsaturated grouping
IT1258788B (it) * 1992-01-17 1996-02-29 Giuliani Spa Derivati solforati di acidi biliari
ES2111092T3 (es) * 1992-06-12 1998-03-01 Hoechst Ag Derivados de acidos biliares, procedimiento para su preparacion y utilizacion de estos compuestos como medicamentos.
DK0614908T3 (da) * 1993-03-09 1997-10-13 Hoechst Ag Fremgangsmåde til fremstilling af 3beta-aminocholansyrederivater.
WO1994020520A1 (en) * 1993-03-10 1994-09-15 Magainin Pharmaceuticals Inc. Steroid derivatives, pharmaceutical compositions containing them, and their use as antibiotics or disinfectants
TW289021B (fi) * 1993-05-08 1996-10-21 Hoechst Ag
TW289757B (fi) * 1993-05-08 1996-11-01 Hoechst Ag
EP0624593A3 (de) * 1993-05-08 1995-06-07 Hoechst Ag Gallensäurederivate, Verfahren zu ihrer Herstellung und Verwendung dieser Verbindungen als Arzneimittel.
TW289020B (fi) * 1993-05-08 1996-10-21 Hoechst Sktiengesellschaft
US5624963A (en) * 1993-06-02 1997-04-29 Geltex Pharmaceuticals, Inc. Process for removing bile salts from a patient and compositions therefor
US5585470A (en) * 1994-06-23 1996-12-17 Transcell Technologies, Inc. Process for the manufacture of 3-amino-substituted glycosylated bile acids
US5856535A (en) * 1994-08-18 1999-01-05 Magainin Pharmaceuticals, Inc. Aminosterol ester compounds
US5840740A (en) * 1995-06-07 1998-11-24 Magainin Pharmaceuticals Inc. Aminosterol compounds and a method of treating infection using the aminosterol compounds
DE4432708A1 (de) * 1994-09-14 1996-03-21 Hoechst Ag Modifizierte Gallensäuren, Verfahren zu ihrer Herstellung und ihre Verwendung
US5583239A (en) * 1995-05-30 1996-12-10 Lehigh University Antimicrobial sterol conjugates
US6143738A (en) * 1995-06-07 2000-11-07 Magainin Pharmaceuticals, Inc. Therapeutic uses for an aminosterol compound
US5994336A (en) * 1995-06-07 1999-11-30 Magainin Pharmaceuticals Inc. Method of inhibiting proliferation of cells by administering an aminosterol compound
US5874597A (en) * 1995-06-07 1999-02-23 Magainin Pharmaceuticals, Inc. Certain aminosterol compounds and pharmaceutical compositions including these compounds
US5795885A (en) * 1995-06-07 1998-08-18 Magainin Pharmaceuticals Inc. Method of inhibiting profileration of cells by administering an aminosterol compound
US5840936A (en) * 1995-06-07 1998-11-24 Magainin Pharmaceuticals Inc. Aminosterol compounds useful as inhibitors of the sodium/proton exchanger (NHE)
US5792635A (en) * 1995-06-07 1998-08-11 Magainin Pharmaceuticals, Inc. Method of inhibiting the sodium/proton exchanger NHE3 and method of inhibiting growth by administering squalamine
US5847172A (en) * 1995-06-07 1998-12-08 Magainin Pharmaceuticals Inc. Certain aminosterol compounds and pharmaceutical compositions including these compounds
US5763430A (en) * 1995-06-07 1998-06-09 Magainin Pharmaceuticals Inc. Method of treating a viral infection by administering a steroid compound
US20040014709A1 (en) * 1996-01-08 2004-01-22 Canji, Inc. Methods and compositions for interferon therapy
US7002027B1 (en) * 1996-01-08 2006-02-21 Canji, Inc. Compositions and methods for therapeutic use
US5789244A (en) * 1996-01-08 1998-08-04 Canji, Inc. Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems
US6392069B2 (en) * 1996-01-08 2002-05-21 Canji, Inc. Compositions for enhancing delivery of nucleic acids to cells
FR2743561B1 (fr) * 1996-01-15 1998-02-20 Fournier Sca Lab Derives de steroides, procede de preparation et utilisation en therapeutique
US6596712B2 (en) 1996-04-26 2003-07-22 Genaera Corporation Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities
ATE242635T1 (de) * 1996-04-26 2003-06-15 Magainin Pharma Squalamin in kombination mit anderen antikrebs- mittelen zur behandlung von tumoren
DE19633268A1 (de) * 1996-08-19 1998-02-26 Hoechst Ag Polymere Gallensäure-Resorptionsinhibitoren mit gleichzeitiger Gallensäure-Adsorberwirkung
US6262283B1 (en) 1996-12-06 2001-07-17 Magainin Pharmaceuticals Inc. Stereoselective synthesis of 24-hydroxylated compounds useful for the preparation of aminosterols, vitamin D analogs, and other compounds
DK0869121T3 (da) * 1997-04-04 2004-09-20 Aventis Pharma Gmbh Hypolipidæmiske propanolaminderivater
DE19845403B4 (de) * 1998-10-02 2005-02-10 Aventis Pharma Deutschland Gmbh Mit Gallensäuren verknüpfte Propanolaminderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
DE19950686B4 (de) * 1999-10-21 2006-06-29 Martin-Luther-Universität Halle-Wittenberg Multifunktionelle Spacer
WO2001042273A2 (en) * 1999-12-09 2001-06-14 Genaera Corporation Asthma associated factors as targets for treating atopic allergies including asthma and related disorders
DE60123939T2 (de) * 2000-04-12 2007-05-31 Genaera Corp. Ein verfahren zur herstellung von 7.alpha.-hydroxy 3-aminosubstituierten sterol-verbindungen, ohne schutz der 7.alpha.-hydroxy-gruppe
US8975246B2 (en) 2001-04-17 2015-03-10 Galmed Research And Development Ltd. Bile acid or bile salt fatty acid conjugates
JP4727923B2 (ja) * 2001-12-20 2011-07-20 シェーリング コーポレイション Ｓｙｎ３組成物およびその方法
US7141559B2 (en) 2002-06-19 2006-11-28 Karo Bio Ab Glucocorticoid receptor ligands for the treatment of metabolic disorders
CA2488535C (en) * 2002-06-19 2012-02-07 Karo Bio Ab Glucocorticoid receptor ligands for the treatment of metabolic disorders
GB0307918D0 (en) 2003-04-05 2003-05-14 Astrazeneca Ab Therapeutic use
US7355056B2 (en) 2003-06-04 2008-04-08 Canji, Inc. Transfection agents
US7235678B2 (en) * 2004-03-30 2007-06-26 Council Of Scientific And Industrial Research Bile acid derived steroidal dimers with novel amphiphilic topology having antifungal activity
US20050225942A1 (en) * 2004-04-07 2005-10-13 First International Computer Inc. Plug-in cooling device
ES2318922B1 (es) * 2005-05-30 2010-02-12 Universidade De Santiago De Compostela Nuevos dimeros derivados de acidos biliares funcionalizados en la posicion 3 del anillo a. metodo para la sintesis y aplicaciones.
ES2318927B1 (es) * 2005-08-25 2010-02-12 Universidade De Santiago De Compostela Nuevos dimeros de acidos biliares funcionalizados en la posicion 24 de la cadena alquilica de la sal biliar. procedimientos para su obtencion y aplicaciones.
US7960439B1 (en) 2006-06-12 2011-06-14 Iowa State University Research Foundation, Inc. Environmentally sensitive foldable oligomers
US7962543B2 (en) * 2007-06-01 2011-06-14 Advanced Micro Devices, Inc. Division with rectangular multiplier supporting multiple precisions and operand types
KR101289199B1 (ko) 2008-08-28 2013-07-29 한양대학교 산학협력단 수용성기를 포함한 바일산 유도체 및 그의 응용
WO2012054092A1 (en) * 2010-01-22 2012-04-26 Trustees Of Dartmouth College Lipid cofactors for facilitating propogation of prpsc
WO2011150286A2 (en) 2010-05-26 2011-12-01 Satiogen Pharmaceuticals,Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
RS60901B1 (sr) 2010-11-08 2020-11-30 Albireo Ab Ibat inhibitori za lečenje oboljenja jetre
MX345040B (es) 2010-11-08 2017-01-16 Albireo Ab Una combinacion farmaceutica que comprende un inhibidor de ibat y un aglutinante de acido biliar.
CN104023718B (zh) 2011-10-28 2017-04-05 鲁美纳医药公司 用于治疗高胆血症和胆汁淤积性肝病的胆汁酸再循环抑制剂
CN104023727B (zh) 2011-10-28 2017-04-05 鲁美纳医药公司 用于治疗小儿胆汁淤积性肝病的胆汁酸再循环抑制剂
AU2014229050A1 (en) 2013-03-15 2015-10-22 Lumena Pharmaceuticals Llc Bile acid recycling inhibitors for treatment of Barrett's esophagus and gastroesophageal reflux disease
AU2014228850A1 (en) 2013-03-15 2015-10-29 Lumena Pharmaceuticals Llc Bile acid recycling inhibitors for treatment of primary sclerosing cholangitis and inflammatory bowel disease
JO3301B1 (ar) 2013-04-26 2018-09-16 Albireo Ab تعديلات بلورية على إيلوبيكسيبات
CA2952406A1 (en) 2014-06-25 2015-12-30 Ea Pharma Co., Ltd. Solid formulation and method for preventing or reducing coloration thereof
EP3012252A1 (en) 2014-10-24 2016-04-27 Ferring BV Crystal modifications of elobixibat
US10441604B2 (en) 2016-02-09 2019-10-15 Albireo Ab Cholestyramine pellets and methods for preparation thereof
US10441605B2 (en) 2016-02-09 2019-10-15 Albireo Ab Oral cholestyramine formulation and use thereof
CN108601744B (zh) 2016-02-09 2022-01-04 阿尔比里奥公司 口服考来烯胺制剂及其用途
US10786529B2 (en) 2016-02-09 2020-09-29 Albireo Ab Oral cholestyramine formulation and use thereof
RU2750937C2 (ru) 2016-02-09 2021-07-06 Альбирео Аб Пероральный состав холестирамина и его применение
JP7328207B2 (ja) 2017-08-09 2023-08-16 アルビレオ・アクチボラグ コレスチラミンペレット、経口コレスチラミン製剤、及びそれらの使用
CA3071285A1 (en) 2017-08-09 2019-02-14 Albireo Ab Cholestyramine granules, oral cholestyramine formulations and use thereof
WO2019148294A1 (en) 2018-02-02 2019-08-08 Interface Biologics, Inc. Dimeric dexamethasone prodrug compositions and uses thereof
JP7391048B2 (ja) 2018-06-05 2023-12-04 アルビレオ・アクチボラグ ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
US10793534B2 (en) 2018-06-05 2020-10-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
CA3100691A1 (en) 2018-06-20 2019-12-26 Albireo Ab Crystal modifications of odevixibat
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
CA3127408A1 (en) 2019-02-06 2020-08-13 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
US10975045B2 (en) 2019-02-06 2021-04-13 Aibireo AB Benzothiazepine compounds and their use as bile acid modulators
FI3921028T3 (fi) 2019-02-06 2023-01-31 Bentsotiadiatsepiinin yhdisteet ja niiden käyttö sappihapon modulaattoreina
US10941127B2 (en) 2019-02-06 2021-03-09 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
JP2022520121A (ja) 2019-02-12 2022-03-28 ミルム ファーマシューティカルズ インコーポレイテッド 胆汁うっ滞を治療する方法
CA3158181A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
WO2021110886A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
TW202134218A (zh) 2019-12-04 2021-09-16 瑞典商艾爾比瑞歐公司 苯并噻氮呯化合物及其作為膽酸調節劑之用途
JP2023504645A (ja) 2019-12-04 2023-02-06 アルビレオ・アクチボラグ ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
WO2021110883A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
TW202134222A (zh) 2019-12-04 2021-09-16 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯化合物及其作為膽酸調節劑之用途
EP4069247A1 (en) 2019-12-04 2022-10-12 Albireo AB Benzothiadiazepine compounds and their use as bile acid modulators
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
CN114786772B (zh) 2019-12-04 2024-04-09 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
TW202134221A (zh) 2019-12-04 2021-09-16 瑞典商艾爾比瑞歐公司 苯并噻二氮呯化合物及其作為膽酸調節劑之用途
WO2021220061A2 (en) 2020-05-01 2021-11-04 Ripple Therapeutics Corporation Heterodimer compositions and methods for the treatment of ocular disorders
JP2023537285A (ja) 2020-08-03 2023-08-31 アルビレオ・アクチボラグ ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
WO2022029101A1 (en) 2020-08-03 2022-02-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
EP4243831A1 (en) 2020-11-12 2023-09-20 Albireo AB Odevixibat for treating progressive familial intrahepatic cholestasis (pfic)
JP2024500309A (ja) 2020-12-04 2024-01-09 アルビレオ エービー ベンゾチア（ジ）アゼピン化合物および胆汁酸モジュレータとしてのその使用
TW202313579A (zh) 2021-06-03 2023-04-01 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途
WO2023216423A1 (zh) * 2022-05-13 2023-11-16 苏州慧疗生物医药科技有限公司 脂质化合物及其组合物，制备和用途
US20230398125A1 (en) 2022-06-09 2023-12-14 Albireo Ab Treating hepatitis
WO2024008766A1 (en) 2022-07-05 2024-01-11 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
US20240207286A1 (en) 2022-12-09 2024-06-27 Albireo Ab Asbt inhibitors in the treatment of renal diseases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4418059A (en) * 1981-07-20 1983-11-29 Montefiore Medical Center Nucleoside ester compositions
IT1210874B (it) * 1982-04-15 1989-09-29 Istituto Chemioterapico Sale di magnesio dell'acido chenodesossicolico e dell'acido ursodesossicolico, processo per lasua preparazione e composizioni terapeutiche che lo contengono come principio attivo.
EP0202703B1 (en) * 1985-05-15 1989-08-09 N.V. Gantax Pharmaceutica Pharmaceutical compositions of the prodrug type, a process for the preparation thereof, a process for the preparation of them as prodrug functioning compounds and compounds obtained therein
DE3742798C2 (de) * 1987-12-17 1997-02-13 Freedom Chemical Co Verfahren zur Herstellung des Magnesium-Doppelsalzes der Chenodesoxycholsäure und Ursodesoxycholsäure

Also Published As

Publication number Publication date
ZA919605B (en) 1992-08-26
FI106800B (fi) 2001-04-12
HRP940751A2 (en) 1997-04-30
HRP940751B1 (en) 2000-12-31
NO914792D0 (no) 1991-12-05
NZ240846A (en) 1994-04-27
EP0489423A1 (de) 1992-06-10
IL100240A0 (en) 1992-09-06
HUT62599A (en) 1993-05-28
EP0489423B1 (de) 1996-11-06
US5250524A (en) 1993-10-05
PT99713B (pt) 1999-05-31
HU211900A9 (en) 1996-01-29
DK0489423T3 (da) 1997-04-14
KR100221690B1 (ko) 1999-10-01
ATE144988T1 (de) 1996-11-15
YU189991A (sh) 1995-10-03
NO914792L (no) 1992-06-09
JP3237882B2 (ja) 2001-12-10
FI915719A (fi) 1992-06-07
ES2096614T3 (es) 1997-03-16
CA2057099A1 (en) 1992-06-07
PT99713A (pt) 1992-10-30
CS369791A3 (en) 1992-06-17
AU649089B2 (en) 1994-05-12
NO304187B1 (no) 1998-11-09
DE59108326D1 (de) 1996-12-12
IE914235A1 (en) 1992-06-17
HU913817D0 (en) 1992-02-28
SI9111899B (sl) 2000-06-30
HU213402B (en) 1997-06-30
KR920012108A (ko) 1992-07-25
CA2057099C (en) 2005-05-17
IL100240A (en) 1995-10-31
SI9111899A (sl) 1998-04-30
CZ281075B6 (cs) 1996-06-12
AU8884991A (en) 1992-06-11
JPH05294988A (ja) 1993-11-09
GR3021572T3 (en) 1997-02-28
YU48636B (sh) 1999-03-04

Similar Documents

Publication Publication Date Title
FI915719A0 (fi) Gallsyraderivat, foerfarande foer deras framstaellning och anvaendning av denna foerening som laekemedel.
NO914092D0 (no) Fremgangsmaate for fremstilling av mercaptoacetylamidderivater
DE69627769D1 (de) Funktionelle Faserprodukte
FI883249A (fi) Menetelmä terapeuttisesti käyttökelpoisten 3-desmetyylimevalonihappojohdannaisten valmistamiseksi
PT93246A (pt) Processo para a preparacao de compostos pirrolicos substituidos e de composicoes farmaceuticas que os contem
PT814797E (pt) Composicoes farmaceuticas parentericas que contem sais de alquilamonio de acidos 2-arilpropionicos
DK162883D0 (da) N-glucosylerede carboxylsyreamidderivater, fremgangsmade til fremstilling heraf samt deres anvendelse til pavirkning af organismens egen forsvarsmekanisme
FI924478A (fi) 24-oxa-derivat i vitamin d-serien
PT90362A (pt) Metodo para o tratamento de doencas muco-epiteliais e da pele em mamiferos que utiliza acidos 4-quinolinocarboxilicos e seus derivados e processo para a preparacao de composicoes farmaceuticas que contem os mesmos compostos
FI902901A0 (fi) Dibenzol/1,5/dioxocin-5-one-derivat, deras anvaendning i laekemedel och foerfarande foer deras framstaellning.
FI954138A (fi) Hydroksimetyylifuratsaanikarboksyylihappojohdannaiset ja niiden käyttö sydänverisuonitautien käsittelyssä
MA23133A1 (fr) Derives d'acide d'acyloxyhexanoique .
ES2087421T3 (es) Acidos (1's)-hidroxialquiloxapenem-3-carboxilicos y su uso como inhibidor de la betalactamasa.
DE69509822D1 (de) Verfahren zur Herstellung von Ascorbinsäurederivaten
DE69625562D1 (de) Verfahren zur Herstellung von optisch aktiven Cyclohexanolderivaten
SE8502286L (sv) Estrar for framstellning av en beta-laktamasinhibitor
DE59609672D1 (de) Verfahren zur Herstellung von Salzen substituierter oder unsubstituierter Phthalsäure-Derivate
DE69201873D1 (de) Verfahren zur Herstellung optisch aktiver Dihydropyranderivate.
ATE73812T1 (de) Thionophosphonsaeureester.
DE68928788D1 (de) Verfahren zur Herstellung von optisch aktiven 3,4-Dihydroxybuttersäurederivaten
IT9020110A0 (it) Metodo per la purificazione di derivati glicoconiugati di acidi biliari
TH18619EX (th) ไอโซควินโนลีน